OBJECT DRUGS

Chemotherapy agents (CYP3A4 Substrates):

• Abiraterone (Zytiga)
• Anastrozole (Arimidex)
• Aprepitant (Emend)
• Bexarotene (Targretin)
• Bortezomib (Velcade)
• Brentuximab (Adcetris)
• Cabazitaxel (Jevtana)
• Cyclophosphamide (Cytoxan)
• Docetaxel (Taxotere)
• Doxorubicin (Adriamycin)
• Enzalutamide (Xtandi)
• Etoposide (Vepesid)
• Exemestane (Aromasin)
• Ifosfamide (Ifex)
• Ixabepilone (Ixempra)
• Ixazomib (Ninlaro)
• Letrozole (Femara)
• Paclitaxel (Taxol)
• Panobinostat (Farydak)
• Sonidegib (Odomzo)
• Teniposide (Vumon)
• Toremifene (Fareston)
• Trabectedin (Yondelis)
• Venetoclax (Venclexta)

PRECIPITANT DRUGS

Enzyme Inducers:

• Barbiturates
• Bosentan (Tracleer)
• Carbamazepine (Tegretol, etc.)
• Dabrafenib (Tafinlar)
• Efavirenz (Sustiva)
• Etravirine (Intelence)
• Lumacaftor (Orkambi)
• Nevirapine (Viramune, etc.)
• Oxcarbazepine (Trileptal, etc.)
• Phenytoin (Dilantin, etc.)
• Primidone (Mysoline)
• Rifabutin (Mycobutin)
• Rifampin (Rifadin, etc.)
• Rifapentine (Priftin)
• St. John's wort

Comment:

Although data are limited, these enzyme inducers may decrease the plasma levels of chemotherapy agents. Reduction in the expected antineoplastic activity or resistance may occur.

Class 2: Use Only If Benefit Felt to Outweigh Risk

• Monitor: Monitor for altered antineoplastic response if the CYP3A4 inducer is initiated, discontinued, or changed in dosage.